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Abstract
Background: The possibility of using stem cells for regenerative medicine has opened a new field
of investigation. The search for sources to obtain multipotent stem cells from discarded tissues or
through non-invasive procedures is of great interest. It has been shown that mesenchymal stem
cells (MSCs) obtained from umbilical cords, dental pulp and adipose tissue, which are all biological
discards, are able to differentiate into muscle, fat, bone and cartilage cell lineages. The aim of this
study was to isolate, expand, characterize and assess the differentiation potential of MSCs from
human fallopian tubes (hFTs).
Methods: Lineages of hFTs were expanded, had their karyotype analyzed, were characterized by
flow cytometry and underwent in vitro adipogenic, chondrogenic, osteogenic, and myogenic
differentiation.
Results: Here we show for the first time that hFTs, which are discarded after some gynecological
procedures, are a rich additional source of MSCs, which we designated as human tube MSCs
(htMSCs).
Conclusion: Human tube MSCs can be easily isolated, expanded in vitro, present a mesenchymal
profile and are able to differentiate into muscle, fat, cartilage and bone in vitro.
Background
Adult mesenchymal stem cells (MSCs) are typically
defined as undifferentiated multipotent cells endowed
with the capacity for self-renewal and the potential to dif-
ferentiate into several distinct cell lineages [1]. These pro-
genitor cells which constitute a reservoir found within the
connective tissue of most organs are involved in the main-
tenance and repair of tissues throughout the postnatal life
of an individual. Although functionally heterogeneous,
MSC populations isolated from different tissues such as
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bone marrow, skeletal muscle, lung, adipose tissue, dental
pulp, placenta, and the umbilical cord present a similar
profile of cell surface receptor expression [2-10]. However,
it is also well known that adult stem cells are defined by
their functional properties rather than by marker expres-
sion [11].
We and others have recently shown that the umbilical
cord, dental pulp, orbicular oris muscle and adipose tissue
are a very rich source of MSCs able to differentiate into
muscle, cartilage, bone and adipose cell lineages [7,10,12-
15]. The extraordinary regenerative capacity of the human
endometrium following menstruation, in the postpartum
period, after surgical procedures (uterine curettage,
endometrial ablation) and in postmenopausal women
undergoing hormonal replacement therapy suggests that
MSC niches present in this tissue could be responsible for
this process [16]. Indeed, endometrial and menstrual
blood-derived stem cells were recently isolated and
showed the ability to differentiate into cell types of the
three germ layers [17-23].
The human fallopian tubes (hFTs) share the same embry-
ologic origin as the uterus. They have the capacity to
undergo dynamic endocrine-induced changes during the
menstrual cycle, including cell growth and regeneration,
in order to provide the unique environment required for
the maintenance of male and female gamete viability, fer-
tilization, and early embryo development as well as trans-
port to the uterus [24]. Therefore, based on the experience
of our research group in the identification, and character-
ization of potential sources of adult stem cells [7,10,12-
15], the aim of this study was to isolate, expand, charac-
terize and assess the differentiation potential of MSCs
from hFTs.
Methods
Human Fallopian Tube Collection and Processing
Human fallopian tubes (n = 6) were obtained from hyster-
ectomy or tubal ligation/resection samples collected dur-
ing the proliferative phase from fertile women in their
reproductive years (range 35–53 years) who had not
undergone exogenous hormonal treatment for at least
three months prior to surgery. Informed consent was
obtained from each patient and approval granted from by
the ethics committee of the Biosciences Institute of the
University of São Paulo. All laboratory experiments were
carried out at the Human Genome Research Center, São
Paulo, Brazil.
Each sample was collected in HEPES-buffered Dulbecco
Modified Eagle Medium/Hams F-12 (DMEM/F-12; Invit-
rogen, Carlsbad, CA) or DMEM high glucose (DMEM/
High; Invitrogen, Carlsbad, CA) supplemented with 10%
fetal bovine serum (FBS; HyClone, Logan, UT), kept in
4°C and processed within 24 hours period. All hFTs sam-
ples were washed twice in phosphate saline buffer (PBS,
Gibco, Invitrogen, Carlsbad, CA), finely minced with a
scalpel, put inside a 15 or 50 mL falcon, and incubated in
5 ml of pure TripLE Express, (Invitrogen, Carlsbad, CA n)
for 30 minutes, at 37°C, in a water bath. Subsequently,
supernatant was removed with a sterile Pasteur pipette,
washed once with 7 mL of DMEM/F-12 supplemented
with 10% FBS in a 15 mL falcon, and pelleted by centrifu-
gation at 400 g for five minutes at room temperature.
Cells were then plated in DMEM/F-12 (5 mL) supple-
mented with 10% FBS, 100 IU/mL penicillin (Invitrogen)
and 100 IU/mL streptomycin (Invitrogen, Carlsbad, CA)
in plastic flasks (25 cm2), and maintained in a humidified
atmosphere of 5% CO2 in air at 37°C. The culture
medium used for expansion was initially changed every
72 hours and routinely replaced twice a week thereafter.
Population Doubling (PD) and Karyotypic Analysis
PD experiments were carried out to verify the growth rate
of cell lineages for at least five consecutive days, both dur-
ing the process of establishment and long-term passages.
To calculate the growth rate the methodology previously
described by Deasy et al. was used [25].
Karyotypic analysis of cells from the same lineages under-
going PD experiments was performed to verify mainte-
nance of chromosomal normality. Cells were cultured for
one hour in colchicine (0.1 μg/mL), detached using Tri-
pLE Express (Invitrogen, Carlsbad, CA), washed in PBS
(Gibco – Invitrogen, Carlsbad, CA), and resuspended in
0.5 mL of medium and mixed with .075 M KCl to a vol-
ume of 10 mL. After incubation for 20 minutes at 37°C in
a water bath, the cells were centrifuged at 400 g for five
minutes and the pellet fixed three times in 1 mL of cold
Carnoy's fixative. Three drops of cell suspension were
fixed per slide. For chromosome counting the slides were
stained in Giemsa for 15 minutes and photographed in a
phase-contrast microscope (Ikaros System, Axiophot 2,
Carl Zeiss, Jena, Germany)
Flow Cytometry Analysis
Flow cytometry analysis was performed using a Guava
EasyCyte microcapillary flow cytometer (Guava Technol-
ogies, Hayward, CA) utilizing laser excitation and emis-
sion wavelengths of 488 and 532 nm, respectively. Cells
were pelleted, resuspended in PBS (Gibco – Invitrogen,
Carlsbad, CA) at a concentration of 1.0 × 105 cells/mL and
stained with saturating concentration of antibodies. After
45 minute incubation in the dark at room temperature,
cells were washed three times with PBS (Gibco, Invitro-
gen, Carlsbad, CA) and resuspended in 0.25 mL of cold
PBS.
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In order to analyze cell surface expression of typical pro-
tein markers, adherent cells were treated with the follow-
ing anti-human primary antibodies: CD13-phycoerythrin
[PE] (Becton Dickinson, Franklin Lakes, NJ), CD14
(VMRD Inc., Pullman, WA), CD29-PE-Cy5, CD31-PE,
CD34-PerCP, CD38-fluorescein isothiocyanate [FITC],
CD44-FITC, CD45-FITC, CD73-PE, CD90-R-PE, CD117-
PE (Becton Dickinson, Franklin Lakes, NJ), CD133-PE
(Miltenyi Biotec, Gladbach, Germany), human leukocyte
antigens (HLA)-ABC-FITC and HLA-DR-R-PE (Becton
Dickinson, Franklin Lakes, NJ), SSEA4 (Chemicon,
Temecula, CA), STRO1 (R&D Systems, Minneapolis,
MN), and SH2, SH3 and SH4 (kindly provided by Dr.
Kerkis, Butantan Institute, São Paulo, Brazil). Unconju-
gated markers were reacted with anti-mouse PE secondary
antibody (Guava Technologies, Hayward, CA). Unstained
cells were gated on forward scatter to eliminate particulate
debris and clumped cells. A minimum of 5.000 events
were counted for each sample.
Mesenchymal Stem Cell Differentiation
To evaluate the properties of mesenchymal stem cell dif-
ferentiation, adherent cells (3rd and 11th passages) under-
went in vitro adipogenic, chondrogenic, osteogenic, and
myogenic differentiation according to the following pro-
tocols:
Adipogenic Differentiation
The adipogenic differentiation capacity of culture-
expanded hFTs cells was determined as previously
reported [26]. Cultured-expanded cells from hFTs were
cultured in proliferation medium supplemented with 1
μM dexamethasone, 500 μM 3-isobutyl-1-methylxan-
thine, 60 μM indomethacin, and 5 μg/mL insulin (Sigma-
Aldrich, St. Louis, MO). Confirmation of adipogenic dif-
ferentiation was obtained on day 21 by intracellular accu-
mulation of lipid-rich vacuoles stainable with oil red O
(Sigma-Aldrich, St. Louis, MO). For the oil red O stain
cells were fixed with 4% paraformaldehyde (PFA) for 30
minutes, washed, and stained with a working solution of
0.16% oil red O for 20 minutes.
Chondrogenic Differentiation
Approximately 2.5 × 105 hFTs were centrifuged in a 15 mL
polystyrene tube at 500 g for five minutes, and the pellet
resuspended in 10 mL of basal medium. The basal
medium consisted of DMEM/High (Invitrogen, Carlsbad,
CA) supplemented with 1% ITS-Premix (Becton Dickin-
son, Franklin Lakes, NJ), 1% 10 mM dexamethasone
(Sigma-Aldrich, St. Louis, MO), 1% 100 mM sodium
pyruvate (Gibco – Invitrogen, Carlsbad, CA), and 1% 5
mM ascorbic acid-2 phosphate (Sigma-Aldrich, St. Louis,
MO). Without disturbing the pellet, cells were resus-
pended in 0.5 mL of chondrogenic differentiation
medium, consisting of the basal medium supplemented
with 10 ng/mL transforming growth factor (TGF) β1
(R&D Systems, Minneapolis, MN) and 10% FBS, main-
tained in a humidified atmosphere of 5% CO2 in air at
37°C.
On day one, tubes were gently turned over to acquire a
single floating cell sphere. Medium was changed every
three or four days. On day 21, samples were fixed in 10%
formalin for 24 hours at 4°C and paraffin-embedded.
Cryosections (5 μm thick) were cut from the harvested
micromasses and stained with toluidine blue to demon-
strate extracellular matrix mucopolysaccharides [14].
Osteogenic Differentiation
Osteogenic differentiation was obtained by culturing hFTs
cells in DMEM low glucose (DMEM/LG; Invitrogen,
Carlsbad, CA) supplemented with 0.1 mM dexametha-
sone and 50 mM ascorbic acid-2 phosphate (both Sigma-
Aldrich, St. Louis, MO) and maintained in a humidified
atmosphere of 5% CO2 in air at 37°C. On day nine, 10
mM β-glycerolphosphate was added to induce mineraliza-
tion. Osteogenic differentiation was shown by formation
of calcium-hydroxyapatite-positive areas (von Kossa
staining) on day 21. After two washes with PBS (Gibco –
Invitrogen, Carlsbad, CA) and one with distilled water,
the cells were incubated in 1% silver nitrate (Sigma-
Aldrich, St. Louis, MO) under ultraviolet light for 45 min-
utes. The cells were then incubated in 3% sodium thiosul-
fate (Sigma-Aldrich, St. Louis, MO) for 5 minutes.
Counterstaining was finally performed with Van Gieson
[14]. The calcium accumulation was indicated by dark
color.
Myogenic Differentiation
For myogenic differentiation hFTs cells were cultured in
myogenic differentiation medium consisting of 50%
induction medium and 50% fresh DMEM/F-12 (Invitro-
gen, Carlsbad, CA) supplemented with 10% FBS
(HyClone, Logan, UT) in a humidified atmosphere of 5%
CO2 in air at 37°C.
Proliferation medium, which consists of DMEM/F-12
supplemented with 10% FBS, 100 IU/mL penicillin (Inv-
itrogen, Carlsbad, CA), and 100 IU/mL streptomycin (Inv-
itrogen, Carlsbad, CA), is in fact the same medium used
previously to cultivate primary human myoblasts for 48
hours. Prior to its use, induction medium was filtered
through a 0.22 μm pore membrane filter (Millipore, Bill-
erica, MA) and pH was adjusted with sodium bicarbonate
(Sigma-Aldrich, St. Louis, MO). The hFTs MSCs were cul-
tured for 40 days and the medium changed twice a week.
After this interval, cells were analyzed using Immunofluo-
rescence (IF) and Western blot (WB) testing.
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Immunofluorescence and Western Blot Analysis
Immunofluorescence (IF)
Immunofluorescence localization of dystrophin was per-
formed on muscle-differentiated hFTs cells to confirm
myogenic differentiation. Cells were washed twice with
cold PBS (Gibco – Invitrogen, Carlsbad, CA), fixed with
4% PFA/PBS for 20 minutes at 4°C, and permeabilized
with .05% Triton X-100 (TX-100; Sigma-Aldrich, St. Louis,
MO) in PBS (Gibco – Invitrogen, Carlsbad, CA) for five
minutes. After blocking non-specific binding 10% FBS/
PBS (Invitrogen, Carlsbad, CA) for one hour at room tem-
perature, incubations with the primary antibody (anti-
dystrophin; Ab15277; Abcam, Cambridge, UK) overnight
at 4°C and the secondary antibody (FITC IgG; Chemicon,
Temecula, CA) for one hour at room temperature were
performed. Nuclei were counterstained with 4',6-diamid-
ino-2-phenylindole (DAPI; Sigma-Aldrich, St. Louis, MO)
for visualization. As positive controls, we used normal
human differentiated myotubes cultures. As negative con-
trols, we used non-diferentiated htMSCs. The immunoflu-
orescence slides were examined using an Axiovert 200
microscope (Axio Imager Z1, Carl Zeiss, Oberkochen,
Germany).
Western Blot
Proteins of muscle-differentiated hFTs cells were extracted
by treatment with a buffer containing 10 mM Tris-HCL
[pH 8.0], 150 mM Nacl, 5 mM EDTA, 1% TX-100, and 60
mM octyl glucoside (Sigma-Aldrich, St. Louis, MO). Sam-
ples were centrifuged at 13.000 g for 10 minutes to
remove insoluble debris. Proteins were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE 6%) and transferred onto nitrocellulose
membranes (Amersham Biosciences, Piscataway, NJ). All
membranes were stained with 0.2% Ponceau S (Sigma-
Aldrich) to evaluate the amount of loaded proteins. Mem-
branes were blocked for one hour at room temperature
with 5% milk powder in Tris-buffered saline with Tween
20 detergent (TBST, 20 mM Tris-HCL, 500 mM NaCl,
.05% Tween 20) and treated overnight with anti-dys-
trophin (VP-D508; Vector Laboratories, Burlingame, CA)
and anti-skeletal myosin (M7523; Sigma-Aldrich, St.
Louis, MO) primary antibodies. The following day, mem-
branes were incubated for one hour at room temperature
with peroxidase-conjugated anti-mouse and anti-rabbit
IgG secondary antibodies (GE Healthcare, Piscataway, NJ)
as recommended by the manufacturer. Immunoreactive
bands were detected using the Enhanced Chemolumines-
cence Detection System (GE Healthcare, Piscataway, NJ).
Results
Lineages Expansion, Population Doubling (PD) and 
Karyotype analysis
After plating hFTs cells, different cell types were observed
but most were spindle-shaped, resembling fibroblasts.
Some clusters of cells with endothelial appearance, which
spread weakly, could also be observed (figure 1). After the
first enzymatic dissociation, usually between 5–7 days of
culture, adherent cells were constituted of homogeneous
cell layers with a MSC-like phenotype. All lineages were
expanded, frozen and thawed several times. PD experi-
ments showed high rates of cell division and karyotypic
analysis showed no evidence of chromosomal abnormal-
ities (figure 2).
Flow Cytometry Analysis
All adherent cells derived from hFTs did not express
hematopoietic lineage markers (CD34, CD38, CD45,
CD117 and CD133), endothelial marker CD31 and
monocyte marker (CD14). In addition, the majority of
cells expressed high levels of adhesion markers (CD29,
CD44 and CD90) and MSCs markers (CD13, CD73, SH2,
Morphology of adherent cells when isolated from hFTs (primary cultures)Figure 1
Morphology of adherent cells when isolated from hFTs (primary cultures). A): Cells cultured for three days after ini-
tial plating. Cells with an MSC-like phenotype and a small cluster of cells with endothelial appearance (arrows) (100×). B): Cells 
cultured for six days after initial plating (100×). C) Cells cultured for six days after initial plating (400×). (Microscope Zeiss 
Axiovert 200).
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SH3 and SH4). The isolated cells from hFTs were also pos-
itive for HLA-class I (HLA-ABC) but negative for HLA-class
II (HLA-DR), and negative as well for the embryonic stem
cell factor SSEA4 and the presumed MSC marker Stro1.
For a comparative investigation, we provided a cytometry
analysis of freshly digested and not cultured hFT, where
we used 9 mesenchymal stem cells markers (CD13, CD29,
CD44, CD73, CD90, Stro-1, SH2, SH3 and SH4), as well
as tissue specific markers (CD14, CD31 and CD34). The
cytometry analysis summarized in figure 3 shows the mes-
enchymal profile for hFTs cells. Additionally, MSC prop-
erties of isolated cells were further confirmed with cell
differentiation studies. Surprisingly, CD29 and CD44
were positively expressed in htMSC and in freshly digested
and not cultured hFTs.
Multilineage Differentiation
The plasticity of adherent cells obtained from hFTs was
assessed three weeks after mesodermal induction for oste-
ogenic, adipogenic, and chondrogenic differentiation.
The multilineage differentiation was performed for 5
independent lineages of htMSCs, and no evident differ-
ence in their differentiation potential was observed
between them. In addition, the potential for hFTs cells to
differentiate into skeletal muscle cells was investigated
after 40 days of culture in induction medium. The myo-
genic differentiation was demonstrated by the expression
of myogenic markers (myosin and dystrophin). The hFTs
cells differentiated in myogenic, adipogenic, chondro-
genic, and osteogenic tissues in vitro (figure 4). Together,
these results confirmed the mesenchymal nature of the
isolated cells and their multipotency.
Population doubling and karyotypic analysisFig re 2
Population doubling and karyotypic analysis. Panel A) Results of hFTs lineage in passage two. Panel B) Results of hFTs 
lineage in passage 11. We observed high rates of cell division, with gradual decreasing of the population doubling time (PDT) in 
lineages cultured for a long time. Despite that, no evidence of chromosomal abnormality was observed (Ikaros System, Axio-
phot 2, Carl Zeiss).
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Cytometry analysis of htMSCsFigure 3
Cytometry analysis of htMSCs. Panel A) Analyzed markers, its commitment, its expression (positive or negative) in fresh 
digested hFTs and in htMSCs, and the mean percentage of positive labeled cells and analyzed by flow cytometry (GuavaTech-
nologies, Hayward, CA, http://www.guavatechnologies.com). NP means "not performed". Panel B) Related graphs, where it is 
possible to compare, for each of the 19 analyzed markers, the control sample (not labeled htMSCs) in gray and the experimen-
tal population of htMSCs (labeled with specific antibodies) in black.
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Discussion
The possibility of using stem cells for regenerative medi-
cine has opened a new field of investigation to find the
best sources for obtaining multipotent stem cells, in par-
ticular through non-invasive procedures.
Initially defined as bone marrow precursors, new evidence
suggests that MSCs are present in virtually all organs play-
ing a possibly important role in tissue maintenance and
regeneration [27-31]. More recently, they were also found
in the human uterus endometrium and in menstrual
blood and have been shown capable of promoting regen-
eration in vivo [16,18,19,21,22,32,33]. A recent study
demonstrated isolating stem cells from the endometrium
and promoting in vitro chondrogenesis [20].
It has been shown that MSCs obtained from the umbilical
cord, dental pulp, adipose tissue and menstrual blood, all
biological discards, are able to differentiate into muscle,
fat, bone and cartilage cell lineages [7,10,12-15]. Here we
show for the first time that the hFTs, which are discarded
in hysterectomy procedures, are an additional source rich
in MSCs, which we designated as human tube MSCs
(htMSCs). Early passage htMSCs had longer PD times
(approximately 15 hours). However, with additional pas-
sages, PD times shortened and stabilized. Although
Multilineage differentiation in vitroFigure 4
Multilineage differentiation in vitro. Panel 1) Myogenic differentiation. K represents Kaleidoscope (BioRad, molecular 
marker), nC represents normal control of human skeletal muscle, T represents htMSCs control, Tm represents hFTs cells 
induced for myogenic differentiation. 1A) Dystrophin expression in muscle control and in the induced hFTs cells. 1B) Skeletal 
myosin expression in muscle control and in the induced hFTs cells. 1C) Myosin band observed in the muscle control and in the 
induced hFTs cells by Ponceau S membrane dyeing. 1D) IF assay, indicating dystrophin expression (in green fluorescence) in 
myotubes differentiated from hFTs cells, where nucleuses were colored with DAPI (blue fluorescence) (400×). Panel 2) Oste-
ogenic, chondrogenic and adipogenic differentiation of hFTs cells. 2A) Control hFTs cells (630×). 2B) Osteogenic differentia-
tion (200×). 2C) Chondrogenic differentiation (100×). 2D) Adipogenic differentiation (630×) (Microscope Zeiss Axiovert 200).
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htMSCs proliferate extensively in culture, comparative
analysis of the cells' karyotypes from early (second) and
late (eleventh) passages showed no abnormalities, sug-
gesting chromosomal stability throughout the passages.
Although Nasef et al. suggest that a purified Stro-1-
enriched population augment the suppressive effect in all-
ogeneic transplantation, Murphy et al. showed that alloge-
neic endometrial regenerative cells (ERC or menstrual
blood mesenchymal stem cells), that are Stro-1 negative,
were efficient for the treatment of critical limb ischemia in
rats [34,32]. In accordance to recent studies in human
endometrium, htMSCs are also Stro1 negative [35]. In
other hand, CD44, which is considered a marker of MSCs
and has been shown to be critical for the recruitment of
MSCs into wound sites for tissue regeneration, was highly
expressed in htMSCs and also in the fresh digested fallo-
pian tube tissue [36,37]. CD29, an integrin involved in
cell adhesion was also greatly expressed in all htMSCs
studied lineages, including freshly digested samples. Curi-
ously, according to evidences from recent studies, this
molecule may be involved in the fertilization process,
allowing the binding and fusion of sperm and egg [38].
However, speculation that htMSCs may play a role in
reproduction remains to be elucidated. Anyway, the high
levels of expression of adhesion markers (CD29, CD44
and CD90) and other MSC markers (CD13, CD73, SH2,
SH3 and SH4) together with the multilineage differentia-
tion results confirmed the mesenchymal nature of human
fallopian tube stem cells. These important features imply
that htMSCs represent a cell population that can be rap-
idly expanded for potential clinical applications.
The morphological and functional integrity of the tubal
epithelium are of paramount importance for the develop-
ment of a unique microenvironment required for optimal
fertilization and early embryo development. They are
therefore essential for successful implantation as evi-
denced by a recent meta-analysis showing that the use of
human oviductal cells for co-culture improves embryo
morphology, implantation rates and pregnancy success
[39].
Anatomically the hFTs are divided into four distinct seg-
ments (intramural, isthmic, ampulla, and infundibulum/
fimbria) each one comprised of different populations of
epithelial cells and distinct secretory activity [40]. Bacteria
and viruses constantly found in the lumen of the vagina
may sporadically enter the upper reproductive tract dis-
rupting the hFTs epithelial integrity, and represent a sig-
nificant risk factor to female reproductive health. The
need of a strict homeostasis of hFT environment in order
to avoid the disruption of the reproductive function sug-
gests that MSC niches present in this tissue could be
responsible for this process [41,42].
Recently, Wolff et al. were able to demonstrate the pres-
ence of endometrial multipotent cells by inducing chon-
drogenic differentiation in vitro of a subpopulation of
endometrial stromal cells [20]. However, using non-
endometrial gynecologic tissue such as myometrium, fal-
lopian tube, and uterosacral ligaments as controls, they
could not demonstrate chondrogenesis. This suggests that
there may be less progenitor stem cells in these tissues due
to their lower burden of lifelong regeneration compared
with the endometrium; or that the differentiation assay
employed in their study was not appropriate for these tis-
sues. Based on our success in obtaining myogenic, adipo-
genic, osteogenic, and chondrogenic differentiation from
htMSCs we may presume that the inability to demonstrate
chondrogenesis from fallopian tube tissue reported by
Wolff et al. could be related to methodological issues
rather than to progenitor stem cell concentration.
Conclusion
Human tissue fragments that are usually discarded in sur-
gical procedures may represent important sources of stem
cells and their use does not pose ethical problems. This is
the first study to demonstrate the isolation, in vitro expan-
sion, and differentiation into muscle, fat, cartilage, and
bone of a new rich source of mesenchymal progenitor
cells from normal adult hFTs. Tissue fragments of hFTs,
which are usually discarded after surgical procedures, may
represent a new potential source of pluripotent cells for
regenerative medicine. The identification of niches of tis-
sue-specific stem cells capable of replacing damaged dif-
ferentiated cells in the hFTs may contribute to provide the
unique environment required for the maintenance of
male and female gamete viability, fertilization, and early
embryo development and transport to the uterus, alto-
gether necessary for a successful reproductive outcome.
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